|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
The Future of Prostate Cancer Risk Stratification and Treatment Planning
|
Preston Sprenkle, MD, and Eric Kim, MD
Preston Sprenkle and Eric Kim discuss the future of prostate cancer diagnostics, emphasizing the role of genomic classifiers like PAM50 and MRI in refining patient treatment plans.
|
|
|
|
|
|
|
|
|
|
|
| Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence |
| Daniel Spratt, MD |
| Alicia Morgans speaks with Dan Spratt about the management of biochemical recurrence in prostate cancer post-radical prostatectomy. Dr. Spratt explains the considerations for using hormone therapy alongside salvage radiation, emphasizing the variability in treatment needs based on PSA levels. |
|
|
|
|
|
|
|
|
|
|
|
|
The Molecular Biology of Prostate Cancer
|
Christopher Barbieri, MD, Ph.D.
Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing.
|
|
|
|
|
|
|
|
|
|
|
| Variation in Prostate Cancer Genomic Subtypes Across Prostate MRI PI-RADS Scores and Race
|
| Nimrod Barashi, MD
|
| Nimrod Barashi discussed the variation in prostate cancer genomic subtypes across MRI PI-RADS scores and race. Using mpMRI and genomic classifiers, the study found that the genomic score generally correlated with PI-RADS, but this was weaker for African Americans. Higher PI-RADS scores were linked to more aggressive cancer subtypes, with differences between racial groups. This underscores the need for personalized approaches in prostate cancer management. |
|
|
|
|
|
|
|
|
|
|
| Genomic Classifiers and Artificial Intelligence as Predictors for Treatment Benefit
|
| Daniel Spratt, MD
|
| Daniel Spratt discusses the role of genomic classifiers and artificial intelligence (AI) in predicting treatment benefits for prostate cancer patients. He emphasizes the limitations of the traditional Gleason Score for risk stratification, highlighting the superior predictive value of the Decipher® 22-gene genomic classifier for guiding treatment decisions, particularly the addition of ADT to radiotherapy.
|
|
|
|
|
|
| In Patients Who Receive Salvage Radiation Therapy for BCR, Who Needs Additional Systemic Therapy, What and for How Long?
|
| Daniel Spratt, MD
|
| Daniel Spratt discusses systemic therapy in patients receiving salvage radiation therapy for biochemical recurrence of prostate cancer. He highlights that hormone therapy generally does not improve overall survival in patients receiving early salvage radiotherapy but may benefit those with higher PSA levels. The Decipher 22-gene genomic classifier can further guide treatment decisions by identifying patients at higher risk of recurrence who may benefit from additional therapy.
|
|
|
|
|
|
| How to Manage Active Surveillance - Do We Need a Genetic Biopsy Test to Promote AS in GG2 Cancers?
|
| Matthew Cooperberg, MD, MPH
|
| Matthew Cooperberg discusses the potential role of genetic biopsy tests in promoting active surveillance for Grade Group 2 prostate cancer patients. He emphasizes that GG2 represents a heterogeneous disease state, making risk stratification critical for appropriate AS candidate selection. While clinical risk tools like the CAPRA score are effective, genetic tests like Decipher® provide additional independent prognostic information.
|
|
|
|
|
|
| Genomic Signatures Associated with Adverse Pathologic Features at Radical Prostatectomy Among Active Surveillance Eligible Men |
| Eric Li, MD |
| Eric Li presents the findings on genomic signatures associated with adverse pathologic features at radical prostatectomy among men eligible for active surveillance (AS). The study examined patients with NCCN very low-, low-, and favorable intermediate-risk prostate cancer who underwent Decipher® genomic classifier testing between 2012 and 2023. |
|
|
|
|
|
